These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23558051)

  • 21. Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer.
    O'Shannessy DJ; Jackson SM; Twine NC; Hoffman BE; Dezso Z; Agoulnik SI; Somers EB
    Int J Mol Sci; 2013 Jul; 14(7):13687-703. PubMed ID: 23880844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
    Paek J; Lee M; Nam EJ; Kim SW; Kim YT
    Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.
    Previs R; Leath CA; Coleman RL; Herzog TJ; Krivak TC; Brower SL; Tian C; Secord AA
    Gynecol Oncol; 2015 Aug; 138(2):267-71. PubMed ID: 26037898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of whether serum tumor markers in patients with epithelial ovarian carcinoma change following chemotherapy.
    Li XP; Xu QY; Wang JL; Wang SJ; Zhao Y; Wei LH
    Chin Med J (Engl); 2012 Feb; 125(3):410-5. PubMed ID: 22490394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
    Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
    Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of lamin A but not lamin C expression in epithelial ovarian cancer cells is associated with metastasis and poor prognosis.
    Gong G; Chen P; Li L; Tan H; Zhou J; Zhou Y; Yang X; Wu X
    Pathol Res Pract; 2015 Feb; 211(2):175-82. PubMed ID: 25499720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
    Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.
    Martin LP; Konner JA; Moore KN; Seward SM; Matulonis UA; Perez RP; Su Y; Berkenblit A; Ruiz-Soto R; Birrer MJ
    Gynecol Oncol; 2017 Nov; 147(2):402-407. PubMed ID: 28843653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
    Zhu J; Wang H; Liu CC; Lu Y; Tang H
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2339-45. PubMed ID: 27566683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
    Li T; Xue H; Guo Y; Guo K
    Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.
    Lu L; Schwartz P; Scarampi L; Rutherford T; Canuto EM; Yu H; Katsaros D
    Gynecol Oncol; 2011 Aug; 122(2):366-71. PubMed ID: 21571355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
    Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High level of WAVE1 expression is associated with tumor aggressiveness and unfavorable prognosis of epithelial ovarian cancer.
    Zhang J; Tang L; Shen L; Zhou S; Duan Z; Xiao L; Cao Y; Mu X; Zha L; Wang H
    Gynecol Oncol; 2012 Oct; 127(1):223-30. PubMed ID: 22721732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.